Compare CANF & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CANF | SMTI |
|---|---|---|
| Founded | 1994 | 1982 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 186.9M |
| IPO Year | N/A | N/A |
| Metric | CANF | SMTI |
|---|---|---|
| Price | $0.21 | $22.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.25 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 10.1M | 44.5K |
| Earning Date | 02-03-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $560,000.00 | ★ $101,877,532.00 |
| Revenue This Year | $461.72 | $21.60 |
| Revenue Next Year | N/A | $16.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 30.52 |
| 52 Week Low | $0.17 | $18.90 |
| 52 Week High | $2.33 | $38.68 |
| Indicator | CANF | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 39.03 | 43.72 |
| Support Level | $0.17 | $23.76 |
| Resistance Level | $0.27 | $25.41 |
| Average True Range (ATR) | 0.03 | 1.07 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 33.63 | 3.33 |
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.